A new analysis examines clinical outcomes and risks following transplantation in patients with relapsed or refractory mantle cell lymphoma after ibrutinib exposure. The focus is on how targeted therapy history may influence transplant-related results, including complications and durability of benefit. Mantle cell lymphoma remains difficult to treat in relapsed disease, and ibrutinib has become a common targeted option, making post-ibrutinib decision-making a high-impact clinical question. The report frames transplant as an area where prior drug exposure could affect risk profiles. While the excerpted materials don’t provide full endpoint detail, the study’s central value for the field is its contribution to evidence guiding sequencing of ibrutinib and curative-intent transplant strategies.